A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
about
Recurrent Glioblastoma: Where we standNonsurgical treatment of recurrent glioblastomaFotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas.The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experienceGEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Visualizing molecular profiles of glioblastoma with GBM-BioDP.Bevacizumab at recurrence in high-grade glioma.The future of high-grade glioma: Where we are and where are we going.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.Standards of care for treatment of recurrent glioblastoma--are we there yet?Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experienceHypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience.Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.Passive immunotherapeutic strategies for the treatment of malignant gliomas.Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.Update on treatment strategies for anaplastic glioma: a review of literature.Pharmacologic therapies for malignant glioma: a guide for clinicians.Nitrosoureas in the Management of Malignant Gliomas.E2F transcription factors associated with up-regulated genes in glioblastoma.Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma.Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.A retrospective survey of the last 3 months of life in patients carrying glioblastoma: Clinical treatments and profiles.New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection.
P2860
Q26765042-9F465728-4F8E-4E44-9480-9FF2EAA5AB73Q26795560-43135773-9BDF-47DD-AFE1-084A6CB6D48FQ33411366-F18A4055-DFB0-4CDC-9BDB-851D26436008Q33415187-602D68E4-372D-49C3-88FB-B263D0AF48F9Q33427367-447C4CA5-6FF4-4677-BFB4-5A70BE2851C9Q33432135-D60BB438-BC6D-472D-B57F-1FB2A92BB9F4Q33625227-FD59E95F-7FA0-4314-9723-9BFFB5A653FFQ33881602-39DBEE0E-6BCC-4151-BA85-9AECB6EE70B7Q34045979-2AE1DE51-8049-44B2-A980-F8D92FE6F27AQ35114090-BF997DE6-2B88-46DA-8B45-0E198E5AC579Q35676452-B7B8618C-E863-4930-B0BE-156FA842B1D0Q35686954-9C0A3640-9B41-4211-8FAA-98E608E3D96BQ36500401-E555D99C-4761-4E7F-A1BC-3DA4F3CC15ACQ36935024-2366F943-9477-4F19-AD75-4E09DDBA9F94Q37366417-A88578F0-0329-48EF-84EA-87F0D588E20EQ37526275-9C0043CF-0740-45E1-8AB1-AEE4FF843810Q37699429-8253569F-8146-4ECD-A9F5-9D1826E8E639Q37714783-E5B6619A-6704-4BC6-96F0-ABF4F820302EQ38096437-81E2766C-0499-4098-B6C5-36A79BDA3724Q38205133-AD53D906-1824-40AF-8566-680B8D00F34CQ38209678-B838CA9C-2702-4392-867A-C0018E3D0338Q38214573-EA37E80D-0BF3-4E8A-A8D6-6DC14F239678Q38268897-3789DE9C-D9DE-4005-BED1-31B2DE870BD2Q38691732-672F86C1-D9BA-4942-8467-4F8EAF4CB4DBQ38725917-1BA7032E-AEDE-4F44-AD5F-48835095BF60Q39033903-6CA42E12-5AE7-460A-B874-E6492BC70FE3Q45249503-BBAF16F0-82DC-4545-BC04-F2481D01A09BQ47827536-72AE12D4-D697-410F-8625-72B654948368Q52691329-B8C5845C-A6AD-435D-8FE2-60D81866A2DD
P2860
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A new schedule of fotemustine ...... s with relapsing glioblastoma.
@ast
A new schedule of fotemustine ...... s with relapsing glioblastoma.
@en
type
label
A new schedule of fotemustine ...... s with relapsing glioblastoma.
@ast
A new schedule of fotemustine ...... s with relapsing glioblastoma.
@en
prefLabel
A new schedule of fotemustine ...... s with relapsing glioblastoma.
@ast
A new schedule of fotemustine ...... s with relapsing glioblastoma.
@en
P2093
P2860
P50
P1476
A new schedule of fotemustine ...... ts with relapsing glioblastoma
@en
P2093
Alberto Abbruzzese
Ciro Parlato
Gregorio Cennamo
M Serena De Santi
Marco Carraturo
Michele Genovese
Salvatore Del Prete
Vincenzo Faiola
P2860
P2888
P304
P356
10.1007/S11060-010-0329-Z
P577
2010-08-10T00:00:00Z
P5875
P6179
1050864060